generation flow cytometry
mechanisms of malignant transformation
disease dissemination
malignant clones
ultra-chemoresistant MRD cells
ultra-chemoresistant minimal residual disease
RNA-sequencing
multiple myeloma Multiple myeloma
tumour cells
signature of CTCs
sustained disease control
chemoresistance
cellular mechanisms
persistent residual benign clones
cancer stem cells
selected group of patients
vast majority of patients
role of immune surveillance
targeted research
hierarchical place of putative CSCs
optimal response
depth of response
genomic landscape of benign
ground-breaking research program
dramatic relapses
numbers
pathway of curability
patientsâ€™ outcome
prospective patient samples
optimized DNA
professional subclones responsible
scope of well-controlled clinical trials
low-cell
long-term survival
unique model
innovative approach
scientific proposal
use
therapy
design novel therapeutic
deep remissions
additional key players
functional cures
substantial improvement
expertise
requirements
time
effort